Forums

Oh bother! No forums were found here!

Fintech
Benzinga BioTech
Investment News
Stocks to Watch
Finance
Most Popular News Articles
Bitcoin News
Cramers Picks
Technology News
Stocks and Commodities
Daily Technical Analysis
CGC
Featured Stock
Emerging Markets
Economy
Investing
Options
Real Estate News
Nasdaq Stock News
Latest Articles in Real Estate
Mstardom Finance
Food and Drug Administration--Press Releases
What's New: Drugs RSS Feed
OTC Markets Group - News, Filings & Corporate Actions
ECB - European Central Bank
FRB: Press Release - All Releases
Press Releases
St. Louis Fed - Recent Research
Research Announcements – St. Louis Fed Economic Research
Economic Education
Investor Alerts and Bulletins
SEC.gov Updates: Litigation Releases
SEC.gov Updates: Proposed Rules

Print EZ Provides Notice

16 February 2019 - PRNewswire

MONROE, N.Y., Feb. 15, 2019 /PRNewswire/ -- Print EZ is taking steps ...

Full story available on Benzinga.com

The Week Ahead In Biotech: Conferences, Clinical Trials And Earnings

15 February 2019 - Shanthi Rexaline

Biotech stocks got some reprieve in this week amid the release of earnings, clinical trial results presentations and positive FDA actions.

Among the noteworthy developments of the week:

The FDA panel ruling in favor of Johnson & Johnson (NYSE: JNJ)'s investigational therapy for treatment-resistant depression; The agency's approval of Novartis AG (NYSE: NVS)'s liver fluke infestation drug Egaten and a split-dosing regimen of J&J unit Janssen's Darzalex for multiple myeloma; Gilead Sciences, Inc. (NASDAQ: GILD)'s NASH candidate flunking a late-stage study.

Here are some key developments that a biotech investor should focus on next week.

Conferences 11th International Conference on Vascular Dementia – Feb. 15-16, in Amsterdam, Netherlands Amsterdam, Netherlands 30th European Heart Diseases and Heart Failure Congress – Feb. 18-19, in Amsterdam, Netherlands 14th Annual Conference on Nephrology & Renal Care – Feb. 18-19, in Singapore City, Singapore World Congress on Pain Medicine and Management – Feb. 20-21, in Singapore City International Meeting on Dermato Oncology – Feb. 20-21, in Dallas, U.S. 27th Annual Congress on Cancer Science and Targeted Therapies – Feb. 20-21, ...

Full story available on Benzinga.com

How to Use Price-To-Sales Ratios to Value Stocks

15 February 2019 - Staff Author

The price-to-sales ratio utilizes a company's market capitalization and revenue to determine its valuation.

Stocks to Watch: DuPont, Nike, KB Home are stocks to watch

27 June 2014

Among the companies whose shares are expected to see active trade in Friday’s session are DuPont, Nike, and KB Home.

Sun Life Financial, Inc. 2018 Q4 - Results - Earnings Call Slides

15 February 2019

Amazon: The Most Undervalued Company Now

15 February 2019

Post Office in Liechtenstein Now Sells BTC

16 February 2019 - Kevin Helms

Post Office in Liechtenstein Now Sells BTC The government-owned post office in Liechtenstein has begun offering a cryptocurrency exchange service. Initially, the post office in the capital city of Vaduz will sell BTC, with four more cryptocurrencies planned. The service is in partnership with Zug-based Värdex Suisse, the operator of “the largest crypto ATM network in Switzerland.” Also read: Indian Supreme Court Moves […]

The post Post Office in Liechtenstein Now Sells BTC appeared first on Bitcoin News.

Long-Term Growth Stocks - Cramer's Mad Money (12/11/18)

12 December 2018

Why the Tesla Model 3 isn't branded as a Model 3

16 February 2019 - Sasha Lekach

Look at the back of your car or the next car passing by. Unless it's an ultraluxury Lamborghini or something similar, you likely just saw which car company made the car (maybe a Honda) as well as which model it is (probably a Civic).

Now look at the backside of a Tesla Model 3, the electric car company's newest sedan.

It's almost entirely bare, save for the Tesla logo above the license plate. (The dual motor version is badged and says "Dual Motor," so there are exceptions.) Its predecessors, Models X and S, out in 2015 and 2012, respectively, didn't get this same treatment — their names were prominently displayed on the backs of the car. But when the new Model 3s first started appearing out of factories and on roads in 2017 the only clue a car was the Model 3 was a Model 3 license plate frame from the dealership. Now that the cars are more abundant, the frames are coming off, and there's little to indicate which car it is. Read more...

More about Design, Tesla, Model 3, Tech, and Transportation

bye bye US

16 February 2019

spx st00f

XRP Now What After The JP Morgan Announcement Today ?

14 February 2019

$0.08c or Less that's what - the writing is on the wall for XRP the coin - not the company. Please look up and read the JP Morgan info and comment below - haters welcome as long as you keep it professional. #crypto #fintech #Bitcoin

CGC - Ascending Channel

15 February 2019

The uptrending channel in CGC gives us a confidence band that the price action is likely to stay within until the trend eventually changes. So far, every test of trendline support on the way up has provided CGC bulls with a low-risk, high-reward buying opportunity for shares. In other words, it could be a "buy the dips” stock. The current resistance level is around $52, a jump of ~8% from its current price around $48. However, should share rise above that resistance level, the stock will climb even higher and above the previous highs of $59.25

APPLE INC

15 February 2019

The share will be positive and will create higher prices. NASDAQ:AAPL

Canopy Growth Earnings: CGC Stock Dips Slightly Ahead of Earnings

15 February 2019

InvestorPlace Stock Market News Stock Advice amp Trading Tips Canopy Growth earnings NYSE CGC are being released later today and CGC stock took a slight hit in anticipation of the company s results which are expected to produce a deeper loss than what

Wall Street points to higher open; Dow futures jump 200 points

22 February 2016

Investing.com Investing.com U.S. stock markets pointed to strong gains at the open on Monday, with the Dow futures briefly jumping more than 200 points as a rebound in oil prices boosted market sentiment. The blue chip Dow futures climbed

December Retail Sales Decline Significantly

14 February 2019

Futures have swung to negative levels following three main economic metrics hitting the tape before Thursday s opening bell Happy Valentine s Day BTW everybody Perhaps early traders are still trying to digest what these figures mean and none are cataclysmic though all are worse

So Much For Doom And Gloom...

15 February 2019

After a dismal fourth quarter disheartened investors needed a snap back rally and they got it in spades The S amp P 500 rallied 15 from the market s lows on December 24 through the end of January That s 15 in six weeks I think it would be fair to say that this is a far

Stocks Finish Mixed After National Emergency Bombshell

14 February 2019

U S stocks started the day deep in the red following a stunningly bad retail sales report sparking murmurs of a potential recession While the major indexes were able to pare much of the losses traders were hit late in the day with news that President Donald Trump plans to declare a

Stocks Bounce Back from Retail Sales Surprise

15 February 2019

The market responded to real economic data on Thursday instead of good vibes from trade negotiations thousands of miles away Unfortunately that data was weaker than expected retail sales which led to a sharp morning selloff But the major indices calmed down and ended the session well off

U.S. Home Sales are Plummeting And Nobody's Sure Why

30 January 2019

The U.S. housing market is crumbling--a worrying indication that an economic catastrophe could be brewing. Yet, nobody seems sure why this is happening in an economy that remains hale and hearty by most measures. But don’t rush to your banker just yet hoping to get an easy deal. Rejections for mortgages and

COURT ORDERS $1 BILLION JUDGMENT AGAINST OPERATORS OF WOODBRIDGE PONZI SCHEME TARGETING RETAIL INVESTORS

15 February 2019 - Glenford Robinson

"This resolution accomplishes one of the SEC's core missions to protect retail investors," said Stephanie Avakian, Co-Director of the SEC's Division of Enforcement. "Mr. Shapiro and other defendants will be held accountable and required to pay substantial penalties for their misconduct." "Our complaint charged that when Woodbridge's fictitious business model collapsed, the company stopped paying investors and filed for Chapter 11 bankruptcy protection," said Eric I. Bustillo, Director of the SEC's Miami Regional Office. "The settlement provides for the return of significant funds to investors."

Statement from FDA Commissioner Scott Gottlieb, M.D., on new policy to improve access and foster price competition for drugs that face inadequate generic competition

15 February 2019

FDA announces new draft guidance titled, Competitive Generic Therapies, to help provide even greater clarity to industry about the CGT pathway.

Additions/Deletions for Prescription and OTC Drug Product Lists

15 February 2019

The list has been updated through December 2017.

Artis Real Estate Investment Trust (ARESF: OTCQX International Premier) | Artis Real Estate Investment Trust Announces Monthly Cash Distribution

15 February 2019

Benoît Cœuré: The euro’s global role in a changing world: a monetary policy perspective

15 February 2019

Agencies extend comment period on proposed standardized approach for calculating the exposure amount of derivative contracts

15 February 2019

Agencies extend comment period on proposed standardized approach for calculating the exposure amount of derivative contracts

SEC Files Charges in Elaborate Microcap Stock Fraud

15 February 2019

The Securities and Exchange Commission today announced charges against four individuals and related businesses for their roles in two microcap frauds and unlawful securities offerings. In sum, the alleged illegal transactions resulted in proceeds of more than $25 million.

According to the SEC’s complaint, from approximately December 2012 to June 2013, microcap stock financier Magna Group, which was founded and owned by Joshua Sason, engaged in a scheme to acquire fake convertible promissory notes supposedly issued by penny stock issuer Lustros Inc. and then to convert those notes into shares of Lustros common stock. The defendants then sold the shares to unsuspecting retail investors, who did not know that the shares were fraudulently acquired and were being sold illegally. The defendants’ sales of the Lustros shares also had the effect of destroying the value of the Lustros shares held by the public. The complaint alleges that Marc Manuel, Magna Group’s former head of research and due diligence, personally negotiated and executed the sham transactions.

The complaint also alleges that in November 2013, Magna Equities II, which also was wholly-owned by Sason, and Manuel, purchased another fake promissory note from Pallas Holdings. Magna Equities II and the note’s issuer, NewLead Holdings Ltd., later agreed to retire the fake debt in exchange for shares of the issuer through a court-approved settlement agreement. To obtain approval of the settlement, Sason and Magna Equities II falsely swore to the court that the fake promissory note was a bona fide debt of NewLead. Kautilya “Tony” Sharma and Perian Salviola, who controlled Pallas Holdings, are alleged to also have participated in the scheme.

“As alleged in our complaint, Magna Group and its co-defendants used fake debt instruments to unlawfully obtain shares in microcap companies, which they then dumped on unsuspecting retail investors,” said Sanjay Wadhwa, Senior Associate Director of the SEC’s New York Regional Office. “This action demonstrates the resolve of the SEC in pursuing fraudsters who use elaborate financing schemes to engage in securities fraud.”

The SEC’s investigation was conducted by Lee A. Greenwood, Philip A. Fortino, John O. Enright, Christopher Ferrante, Diego Brucculeri, and Sheldon L. Pollock of the New York office. The SEC’s litigation will be handled by Messrs. Fortino, Greenwood, Enright, and Alexander M. Vasilescu. The case is being supervised by Mr. Wadhwa.

Gauging Market Responses to Monetary Policy Communication

14 February 2019

By Kevin L. Kliesen, Brian Levine, Christopher J. Waller in Review.

Chinese Royalties

8 February 2019

Read up on what China pays to use U.S. intellectual property.

2019 AP Economics Conference

12 July 2019

Are you a seasoned AP economics instructor, new to teaching AP econ courses, or simply contemplating teaching them? If so, join us as Federal Reserve economists, AP economics exam readers, exam developers and instructors, and St. Louis Fed economic education staff present a program packed with the information you need to be successful.

Investor Bulletin: 10 Investment Tips for 2019

12 February 2019

Whether you are a first-time investor or have been investing for years, here are 10 tips from the SEC’s Office of Investor Education and Advocacy to help you in 2019.

Brian Hirsch et al.

15 February 2019

Settlement Concluded with Broker in Case Alleging Public Offering Allocation Fraudulent Practices

Extension of Comment Period for Updated Disclosure Requirements and Summary Prospectus for Variable Annuity and Variable Life Insurance Contracts

14 February 2019

COURT ORDERS $1 BILLION JUDGMENT AGAINST OPERATORS OF WOODBRIDGE PONZI SCHEME TARGETING RETAIL INVESTORS

“This resolution accomplishes one of the SEC’s core missions to protect retail investors,” said Stephanie Avakian, Co-Director of the SEC’s Division of Enforcement. “Mr. Shapiro and other defendants will be held accountable and required to pay substantial penalties for their misconduct.”

“Our complaint charged that when Woodbridge’s fictitious business model collapsed, the company stopped paying investors and filed for Chapter 11 bankruptcy protection,” said Eric I. Bustillo, Director of the SEC’s Miami Regional Office. “The settlement provides for the return of significant funds to investors.”

SEC Charges Cognizant and Two Former Executives With FCPA Violations

“Bribery to further corporate goals is an illusory path to long-term success. While always the wrong choice, it is particularly egregious when senior executives chart that course for those they lead, as our complaint alleges here. We are committed to holding them accountable for their actions,” said Charles E. Cain, Chief of the SEC Enforcement Division’s FCPA Unit.

FDA Authorizes First Interoperable Insulin Pump Intended to Allow Patients to Customize Treatment Through their Individual Diabetes Management Devices

“Diabetes is a complicated disease that requires close monitoring and carefully tailored treatments. We’ve heard from the patient community that having the ability to customize their own diabetes management devices is important to them. Advances in digital health make more tailored approaches to diabetes care possible,” said FDA Commissioner Scott Gottlieb, M.D. “The marketing authorization of the first ACE insulin pump intended for interoperable use has the potential to aid patients who seek more individualized diabetes therapy systems and opens the door for developers of future connected diabetes devices to get other safe and effective products to patients more efficiently. Because the FDA’s action creates a new regulatory classification, future ACE insulin pumps will be able to go through the more efficient 510(k) review process, helping to advance this innovative technology. We’re committed to advancing new ways to accelerate the development of innovations that can improve patient care while strengthening our pre- and post-market tools for determining the safety and effectiveness of these new technologies.

FDA Warns Patients and Doctors About Recall of Home-use Test Strips Used with Device to Monitor Blood Thinner Warfarin, Not Authorized for Sale in U.S.

“Monitoring warfarin dosing is a critical part of using the drug properly to prevent and treat blood clots. Using faulty strips can lead to errors in medication dosage that could cause serious harm or death in some patients. That’s why it’s so concerning that this distributor continued to sell these test strips in the U.S. even though domestic sales had been stopped due to safety concerns. To reduce risks to patients, we’re warning health care providers and the public about the dangers associated with this product,” said FDA Commissioner Scott Gottlieb, M.D. “Distributing products that are not labeled or authorized for sale in the United States raises significant concerns for us in view of the serious safety issues with these test strip devices, and our work on this matter is not finished. Our top priority is the immediate safety of patients, and we’re taking steps to ensure the products that this company distributed are removed from the market.”

SEC Charges Four Public Companies With Longstanding ICFR Failures

According to the SEC’s orders, year after year, the four companies disclosed material weaknesses in ICFR involving certain high-risk areas of their financial statement presentation. As discussed in the SEC orders, each of the four companies took months, or years, to remediate their material weaknesses after being contacted by the SEC staff. One of the companies is still in the process of remediating its material weaknesses.